• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

奥马珠单抗(茁乐®)治疗由紫外线 A 和可见光引起的光线性荨麻疹失败。

Failure of omalizumab (Xolair®) in the treatment of a case of solar urticaria caused by ultraviolet A and visible light.

机构信息

Dermatology and Allergology, University Hospital Basel, Basel, Switzerland.

出版信息

Photodermatol Photoimmunol Photomed. 2011 Dec;27(6):336-7. doi: 10.1111/j.1600-0781.2011.00624.x.

DOI:10.1111/j.1600-0781.2011.00624.x
PMID:22092741
Abstract

Solar urticaria is a rare photodermatosis probably caused by a chromophore, that - if activated by light of a specific spectrum - binds to mast cell-bound IgE and elicits degranulation. In our patient an action spectrum in ultraviolet A and visible light range was found, in the autologous serum test the presence of a serum chromophore for the same action spectra could be demonstrated, which may underline this pathogenetic hypothesis. Symptoms did not improve using antihistamines and sun protection. Photo hardening was denied from the patient, immunosuppression and plasmapheresis were discussed but not considered. So a treatment with Omalizumab was started that recently was successfully used in 4 case reports. After 3 doses of Xolair® there was no changing in the phototesting results and after 4 doses no subjective improvement.

摘要

光线性荨麻疹是一种罕见的光皮病,可能由一种生色团引起,如果这种生色团被特定光谱的光激活,就会与结合在肥大细胞上的 IgE 结合,并引发脱粒。在我们的患者中,发现了一个在中波紫外线和可见光范围内的作用光谱,在自身血清试验中,可以证明存在与相同作用光谱的血清生色团,这可能支持了这一发病假说。抗组胺药和防晒措施都不能改善症状。患者拒绝光致敏,讨论了免疫抑制和血浆置换,但未予考虑。因此,开始使用奥马珠单抗治疗,最近有 4 例病例报告成功使用了这种方法。使用 Xolair® 3 剂后,光试验结果没有变化,4 剂后也没有主观改善。

相似文献

1
Failure of omalizumab (Xolair®) in the treatment of a case of solar urticaria caused by ultraviolet A and visible light.奥马珠单抗(茁乐®)治疗由紫外线 A 和可见光引起的光线性荨麻疹失败。
Photodermatol Photoimmunol Photomed. 2011 Dec;27(6):336-7. doi: 10.1111/j.1600-0781.2011.00624.x.
2
Monitoring omalizumab treatment efficacy in chronic urticaria by the basophil activation test.通过嗜碱性粒细胞活化试验监测奥马珠单抗治疗慢性荨麻疹的疗效。
Allergol Immunopathol (Madr). 2012 Nov-Dec;40(6):390-2. doi: 10.1016/j.aller.2011.09.009. Epub 2011 Dec 15.
3
[Partial response of solar urticaria to omalizumab therapy].[奥马珠单抗治疗日光性荨麻疹的部分缓解]
Hautarzt. 2017 Jun;68(6):492-496. doi: 10.1007/s00105-016-3913-0.
4
Omalizumab: a review of its use in patients with chronic spontaneous urticaria.奥马珠单抗:用于治疗慢性自发性荨麻疹患者的综述。
Drugs. 2014 Sep;74(14):1693-9. doi: 10.1007/s40265-014-0290-9.
5
An algorithm for treating chronic urticaria with omalizumab: dose interval should be individualized.一种使用奥马珠单抗治疗慢性荨麻疹的算法:给药间隔应个体化。
J Allergy Clin Immunol. 2014 Mar;133(3):914-5.e2. doi: 10.1016/j.jaci.2013.10.015. Epub 2013 Dec 18.
6
Treatment of chronic autoimmune urticaria with omalizumab.用奥马珠单抗治疗慢性自身免疫性荨麻疹。
J Allergy Clin Immunol. 2008 Sep;122(3):569-73. doi: 10.1016/j.jaci.2008.07.006.
7
Omalizumab, an Anti-IgE mAb, receives approval for the treatment of chronic idiopathic/spontaneous urticaria.奥马珠单抗,一种抗 IgE mAb,获批用于治疗慢性特发性/自发性荨麻疹。
J Invest Dermatol. 2015 Jan;135(1):13-15. doi: 10.1038/jid.2014.362.
8
Failure of omalizumab in cholinergic urticaria.奥马珠单抗治疗胆碱能性荨麻疹失败。
Clin Exp Dermatol. 2010 Jun;35(4):e127-9. doi: 10.1111/j.1365-2230.2009.03748.x. Epub 2009 Nov 19.
9
Successful treatment of a bullous urticaria with omalizumab.用奥马珠单抗成功治疗大疱性荨麻疹。
Allergol Int. 2014 Sep;63(3):495-7. doi: 10.2332/allergolint.14-LE-0699.
10
Ultraviolet and visible action spectrum in a case of solar urticaria.一例日光性荨麻疹的紫外线和可见光作用光谱
Arch Dermatol. 1970 May;101(5):520-3.

引用本文的文献

1
New insights into chronic inducible urticaria.慢性诱导性荨麻疹的新见解。
Curr Allergy Asthma Rep. 2024 Aug;24(8):457-469. doi: 10.1007/s11882-024-01160-y. Epub 2024 Jul 19.
2
Solar Urticaria, a Disease with Many Dark Sides: Is Omalizumab the Right Therapeutic Response? Reflections from a Clinical Case Report.日光性荨麻疹:一种存在诸多隐患的疾病——奥马珠单抗是否为恰当的治疗对策?基于一则临床病例报告的思考
Open Med (Wars). 2019 Jun 7;14:403-406. doi: 10.1515/med-2019-0042. eCollection 2019.
3
Urticaria and Angioedema: an Update on Classification and Pathogenesis.
荨麻疹和血管性水肿:分类和发病机制的更新。
Clin Rev Allergy Immunol. 2018 Feb;54(1):88-101. doi: 10.1007/s12016-017-8628-1.
4
Review of Physical Urticarias and Testing Methods.物理性荨麻疹及其检测方法综述。
Curr Allergy Asthma Rep. 2017 Aug;17(8):51. doi: 10.1007/s11882-017-0722-1.
5
Off-Label Uses of Omalizumab.奥马珠单抗的非标签用途。
Clin Rev Allergy Immunol. 2016 Feb;50(1):84-96. doi: 10.1007/s12016-015-8490-y.
6
Physical urticaria.物理性荨麻疹。
Curr Allergy Asthma Rep. 2012 Aug;12(4):281-7. doi: 10.1007/s11882-012-0269-0.
7
Omalizumab for chronic urticaria: a case series and overview of the literature.奥马珠单抗治疗慢性荨麻疹:病例系列及文献综述
Case Rep Dermatol. 2012 Jan;4(1):19-26. doi: 10.1159/000336205. Epub 2012 Jan 30.